BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season
NanoViricides, Inc. (NYSE American: NNVC) said the current severe influenza wave underscores the urgent need for broad-spectrum antiviral therapies capable of addressing influenza, RSV, coronaviruses and other respiratory viruses, citing limitations of seasonal vaccines and existing antivirals that face timing constraints and resistance risks. The Company highlighted its Phase II-stage drug candidate NV-387, a broad-spectrum nanoviricide designed to mimic host-cell features viruses rely on to infect cells, which management believes positions it as a potential first-line, empirical therapy for viral acute and severe acute respiratory infections, with demonstrated preclinical activity against influenza, RSV and coronaviruses and potential applicability across a…
